- sNDA submitted for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC)
- Submission based on MARCH Phase 3 study with high statistical significance (p
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
On 6ix: 6ix.com/news/mirum-pharmaceuticals-submits-supplemental-new-drug-application-to-fda-for-livmarli
Watch Mirum Pharmaceuticals' latest callMirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings CallMirum Pharmaceuticals, Inc. on 6ix
Story so far
- Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
- Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
Earlier from Mirum Pharmaceuticals
- Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
- Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
- Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
- Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
Later from Mirum Pharmaceuticals
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
- Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
- Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis
- Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors
Follow Mirum Pharmaceuticals into a list and get an email when it puts out news.
Follow Mirum Pharmaceuticals